Company intelligence / Profile preview

Kyomei

Ownership: Private
Development stage: Other

Overview

Kyomei has developed a proprietary method to express animal myoglobin in crop leaves, enabling scalable and sustainable production of this key meat-flavoring protein. Their approach aims to deliver more authentic taste and nutrition for plant-based meats by providing the umami flavor typically missing from current alternatives. The technology is pre-commercial but has attracted early-stage investment and filed patents on transgenic plant expression of myoglobin.

Modalities: Recombinant protein (produced in plants)Plant-based production systemMyoglobin protein ingredient for food applications
Industry: Non-Drug Biotech

Partnerships

IndieBio/SOSV accelerator program partnershipUniversity of Oxford academic rootsPlug and Play investor network

Beyond the preview

Go deeper on Kyomei.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kyomei.

Explore the full profile